Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah.
Washington University School of Medicine, St. Louis, Missouri.
J Card Fail. 2015 Jun;21(6):519-34. doi: 10.1016/j.cardfail.2015.04.013. Epub 2015 May 4.
We propose that stage D advanced heart failure be defined as the presence of progressive and/or persistent severe signs and symptoms of heart failure despite optimized medical, surgical, and device therapy. Importantly, the progressive decline should be primarily driven by the heart failure syndrome. Formally defining advanced heart failure and specifying when medical and device therapies have failed is challenging, but signs and symptoms, hemodynamics, exercise testing, biomarkers, and risk prediction models are useful in this process. Identification of patients in stage D is a clinically important task because treatments are inherently limited, morbidity is typically progressive, and survival is often short. Age, frailty, and psychosocial issues affect both outcomes and selection of therapy for stage D patients. Heart transplant and mechanical circulatory support devices are potential treatment options in select patients. In addition to considering indications, contraindications, clinical status, and comorbidities, treatment selection for stage D patients involves incorporating the patient's wishes for survival versus quality of life, and palliative and hospice care should be integrated into care plans. More research is needed to determine optimal strategies for patient selection and medical decision making, with the ultimate goal of improving clinical and patient centered outcomes in patients with stage D heart failure.
我们建议将 D 期晚期心力衰竭定义为尽管接受了优化的药物、手术和器械治疗,但仍存在进行性和/或持续性严重心力衰竭体征和症状。重要的是,进行性下降应主要由心力衰竭综合征驱动。明确晚期心力衰竭的定义,并指定何时药物和器械治疗失败是具有挑战性的,但体征和症状、血液动力学、运动测试、生物标志物和风险预测模型在这一过程中很有用。在 D 期识别患者是一项具有临床重要性的任务,因为治疗方法本质上是有限的,发病率通常是进行性的,生存时间通常较短。年龄、虚弱和社会心理问题会影响 D 期患者的结局和治疗选择。心脏移植和机械循环支持设备是某些患者的潜在治疗选择。除了考虑适应证、禁忌证、临床状况和合并症外,D 期患者的治疗选择还涉及到患者对生存与生活质量的意愿,姑息治疗和临终关怀应纳入护理计划。需要更多的研究来确定患者选择和医疗决策的最佳策略,最终目标是改善 D 期心力衰竭患者的临床和以患者为中心的结局。